X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1793) 1793
Publication (233) 233
Book Chapter (55) 55
Book Review (37) 37
Book / eBook (7) 7
Conference Proceeding (2) 2
Government Document (2) 2
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1305) 1305
index medicus (1179) 1179
oncology (703) 703
cancer (632) 632
female (598) 598
advanced basic science (492) 492
male (471) 471
animals (456) 456
middle aged (440) 440
aged (400) 400
chemotherapy (389) 389
adult (350) 350
care and treatment (251) 251
cell biology (231) 231
treatment outcome (229) 229
research (213) 213
pharmacology & pharmacy (208) 208
analysis (202) 202
tumors (196) 196
dentistry (195) 195
metastasis (190) 190
antineoplastic combined chemotherapy protocols - therapeutic use (186) 186
cell line, tumor (186) 186
advanced solid tumors (183) 183
mice (173) 173
expression (167) 167
health aspects (166) 166
medicine & public health (162) 162
prognosis (159) 159
apoptosis (157) 157
article (156) 156
biochemistry & molecular biology (155) 155
antineoplastic agents - therapeutic use (150) 150
aged, 80 and over (142) 142
breast cancer (140) 140
hematology, oncology and palliative medicine (140) 140
radiotherapy (135) 135
carcinoma (133) 133
squamous-cell carcinoma (133) 133
proteins (129) 129
neoplasm staging (127) 127
therapy (127) 127
neoplasms - drug therapy (126) 126
cisplatin (124) 124
antineoplastic agents - pharmacology (118) 118
materials science, biomaterials (118) 118
engineering, biomedical (117) 117
surgery (113) 113
clinical trials (112) 112
survival (104) 104
development and progression (103) 103
signal transduction (96) 96
disease-free survival (95) 95
cancer therapies (94) 94
immunohistochemistry (94) 94
breast-cancer (93) 93
drug therapy (92) 92
hematology (92) 92
antineoplastic combined chemotherapy protocols - adverse effects (91) 91
medicine, research & experimental (91) 91
dentistry, oral surgery & medicine (87) 87
gene expression (86) 86
medical research (86) 86
medicine (85) 85
review (85) 85
oncology, experimental (84) 84
squamous cell carcinoma (84) 84
cell lung-cancer (83) 83
inflammation (83) 83
survival analysis (83) 83
cancer research (82) 82
phase-ii trial (82) 82
physiological aspects (82) 82
carcinoma, squamous cell - pathology (80) 80
immunotherapy (79) 79
trial (79) 79
genetic aspects (78) 78
breast neoplasms - drug therapy (76) 76
locally advanced head (76) 76
radiation-therapy (76) 76
activation (75) 75
angiogenesis (75) 75
in-vitro (75) 75
fluorouracil - administration & dosage (74) 74
neoplasms - metabolism (72) 72
antineoplastic agents (71) 71
combined modality therapy (71) 71
radiology, nuclear medicine & medical imaging (70) 70
signal transduction - drug effects (70) 70
survival rate (70) 70
dose-response relationship, drug (69) 69
mutation (69) 69
antimitotic agents (68) 68
breast neoplasms - pathology (68) 68
cell proliferation (68) 68
patients (68) 68
risk factors (68) 68
5-fluorouracil (67) 67
fluorouracil (67) 67
cell proliferation - drug effects (65) 65
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1839) 1839
French (6) 6
German (5) 5
Polish (2) 2
Russian (2) 2
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 113 - 125.e5
Background The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell... 
Dermatology | Basal Cell Carcinoma Outcomes with LDE225 Treatment study | hedgehog pathway inhibitor | sonidegib | locally advanced basal cell carcinoma | metastatic basal cell carcinoma | advanced basal cell carcinoma | Locally advanced basal cell carcinoma | Advanced basal cell carcinoma | Metastatic basal cell carcinoma | Sonidegib | Hedgehog pathway inhibitor | HEDGEHOG PATHWAY | MULTICENTER | VISMODEGIB | MANAGEMENT | EFFICACY | GUIDELINES | OPEN-LABEL | DERMATOLOGY | DOSE-ESCALATION | UPDATE | INHIBITOR | Skin Neoplasms - drug therapy | Humans | Middle Aged | Carcinoma, Basal Cell - secondary | Biphenyl Compounds - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Biphenyl Compounds - therapeutic use | Young Adult | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Smoothened Receptor - antagonists & inhibitors | Pyridines - therapeutic use | Skin Neoplasms - pathology | Pyridines - administration & dosage | Double-Blind Method | Survival Rate | Disease Progression | Biphenyl Compounds - administration & dosage | Carcinoma, Basal Cell - drug therapy | Aged | Medical research | Care and treatment | Basal cell carcinoma | Analysis | Patient outcomes | Corn | Medicine, Experimental | Skin | Metastasis | Drug therapy | Cancer
Journal Article
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 72, Issue 6, pp. 1021 - 1026.e8
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 10/2014, Volume 111, Issue 8, pp. 1476 - 1481
Basal cell carcinoma (BCC) is a common malignancy with a good prognosis in the majority of cases. However, some BCC patients develop a more advanced disease... 
SURGERY | Gorlin's syndrome | advanced basal cell carcinoma | GUIDELINES | hedgehog pathway inhibitors | HEDGEHOG-PATHWAY | GIANT | RECURRENCE RATES | NONMELANOMA SKIN-CANCER | ONCOLOGY | SURGICAL EXCISION | INHIBITORS | RADIOTHERAPY | FACE | United Kingdom | Carcinoma, Basal Cell - therapy | Skin Neoplasms - therapy | Humans | Minireview
Journal Article
Annales de Dermatologie et de Venereologie, ISSN 0151-9638, 11/2018, Volume 145, pp. VS36 - VS41
Until recently, advanced BCC were only accessible to a highly morbid surgery not necessarily proving to be carcinologic, and leaving terrible dysmorphic... 
Sonidegib | Immunotherapy | Advanced BCC | Vismodegib | Hedgehog pathway
Journal Article
Journal Article
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, ISSN 0151-9638, 11/2018, Volume 145, pp. 36 - 41
Until recently, advanced BCC were only accessible to a highly morbid surgery not necessarily proving to be carcinologic, and leaving terrible dysmorphic... 
MULTICENTER | Advanced BCC | STEVIE | Hedgehog pathway | DERMATOLOGY | THERAPY | Sonidegib | Immunotherapy | DOUBLE-BLIND | RESISTANCE | Vismodegib | INHIBITOR | HUMAN HOMOLOG
Journal Article
The Oncologist, ISSN 1083-7159, 08/2019, Volume 24, Issue 8, pp. e755 - e764
The Hedgehog pathway inhibitors (HPIs), vismodegib and sonidegib, are increasingly employed in the treatment of patients with advanced basal cell carcinoma... 
Response | Recurrence | Basal cell carcinoma | Advanced | Sonidegib | Follow‐up | Metastatic | Vismodegib | MULTICENTER | MANAGEMENT | OPEN-LABEL | CHEMOTHERAPY | Follow-up | NONMELANOMA SKIN-CANCER | ONCOLOGY | HIGH-RISK | DOUBLE-BLIND | ADVERSE EVENTS
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2018, Volume 24, Issue 9, pp. 2082 - 2091
Purpose: The purpose of this study was to determine a recommended phase II dose and schedule of LY2940680 (taladegib) for safe administration to patients with... 
TRIAL | MULTICENTER | ADVANCED SOLID TUMORS | VISMODEGIB | ONCOLOGY | HEDGEHOG PATHWAY INHIBITOR | SONIDEGIB LDE225 | OPEN-LABEL | MECHANISMS | Slopes | Therapy | Toxicity | Muscles | Fatigue | Nausea | Pharmacology | mRNA | Metastasis | Patients | Biological activity | Metastases | Spasms | Confidence intervals | Experimental design | Hedgehog protein | Safety engineering | Skin | Cancer
Journal Article
Future Oncology, ISSN 1479-6694, 02/2015, Volume 11, Issue 4, pp. 703 - 712
Basal cell carcinoma (BCC) is the most common skin cancer worldwide. Most occur on the head and neck, where cosmetic and functional outcomes are critical. BCC... 
basal cell carcinoma | vismodegib | locally advanced basal cell carcinoma | therapy | HEAD | MANAGEMENT | GUIDELINES | ACQUIRED-RESISTANCE | PERINEURAL SPREAD | MOHS MICROGRAPHIC SURGERY | NONMELANOMA SKIN-CANCER | ONCOLOGY | SURGICAL EXCISION | HEDGEHOG PATHWAY INHIBITOR | RECURRENCE
Journal Article